Published in J Clin Oncol on October 06, 2014
Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be? J Clin Oncol (2015) 0.96
Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest. J Clin Oncol (2015) 0.96
Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol (2016) 0.88
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev (2015) 0.84
Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer (2015) 0.81
Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol (2016) 0.81
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget (2016) 0.80
Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol (2016) 0.79
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget (2016) 0.79
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth. Drug Des Devel Ther (2015) 0.78
Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol (2015) 0.77
Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. Onco Targets Ther (2016) 0.77
Reply to E.C. Smyth et al and E. Elimova et al. J Clin Oncol (2015) 0.75
Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma. Sci Rep (2016) 0.75
Construction of quality of life change patterns: example in oncology in a phase III therapeutic trial (FFCD 0307). Health Qual Life Outcomes (2015) 0.75
Unintentional Long-Term Esophageal Stenting due to a Complete Response in a Patient with Stage UICC IV Adenocarcinoma of the Gastroesophageal Junction. Case Rep Gastroenterol (2016) 0.75
Gastrointestinal cancer: FOLFIRI-improving toxicity in first-line treatment of advanced gastric cancer. Nat Rev Clin Oncol (2014) 0.75
Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer. PLoS One (2017) 0.75
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma. Onco Targets Ther (2016) 0.75
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med (2016) 0.75
Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol (2016) 0.75
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer (2017) 0.75
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open (2016) 0.75
Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol (2017) 0.75
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy. Drug Des Devel Ther (2017) 0.75
A Bayesian network meta-analysis on second-line systemic therapy in advanced gastric cancer. Gastric Cancer (2016) 0.75